Clinical Trial Update: Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation [Phase 3]

View source ↗

Summary

Phase 3 rollover study evaluating ivacaftor in cystic fibrosis patients with CFTR mutations other than G551D; study completed and results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2017-05-12